Pro-opiomelanocortin (POMC) neurons of the arcuate nucleus (ARC) are critical metabolic sensors that promote satiety and energy expenditure through the release of α-melanocyte-stimulating hormone (α-MSH). In Prader-Willi syndrome (PWS), hypothalamic POMC neuron dysfunction contributes to hyperphagia, obesity, and metabolic dysregulation. Understanding POMC neuron biology in PWS provides insights into broader neurodegenerative disease mechanisms, as hypothalamic dysfunction also occurs in Alzheimer's disease, Parkinson's disease, and Huntington's disease.
| Property | Value |
|---|---|
| Primary Location | Arcuate nucleus (ARC) of hypothalamus |
| Secondary Populations | Nucleus tractus solitarius (NTS), ventromedial hypothalamus |
| Cell Type | Excitatory peptidergic |
| Key Neurotransmitters | α-MSH, CART, β-endorphin, glutamate |
| Primary Targets | Paraventricular nucleus (PVN), lateral hypothalamus (LH) |
| Key Markers | POMC, CARTPT, LEPR, MC4R (autoinhibition) |
POMC neurons are the central anorexigenic component of the melanocortin system:
The POMC gene encodes a precursor protein that undergoes tissue-specific processing:
| Processing Enzyme | Products | Primary Location |
|---|---|---|
| Prohormone convertase 1/3 (PC1/3) | Pro-ACTH, β-lipotropin | Pituitary |
| Prohormone convertase 2 (PC2) | α-MSH, β-endorphin | Hypothalamus |
| Carboxypeptidase E | Final trimming | All POMC neurons |
| Peptidyl-α-amidating enzyme | α-MSH amidation | Hypothalamus |
α-MSH binding to MC4R activates:
PWS results from loss of paternally expressed genes on chromosome 15q11-q13:
| Genetic Mechanism | Frequency | Key Genes Affected |
|---|---|---|
| Paternal deletion | 70% | SNURF-SNRPN, NDN, MAGEL2, MKRN3 |
| Maternal uniparental disomy (mUPD) | 25% | Imprinted gene silencing |
| Imprinting center defect | 3-5% | Epigenetic dysregulation |
The arcuate nucleus is developmentally affected in PWS:
| Feature | POMC Contribution | Pathophysiology |
|---|---|---|
| Hyperphagia | Reduced α-MSH signaling | Impaired MC4R activation |
| Obesity | ↓ Energy expenditure, ↑ intake | Hypothalamic set-point elevation |
| Growth hormone deficiency | GHRH neuron dysregulation | ARC → PVN pathway affected |
| Hypogonadism | GnRH disruption | Metabolic sensing failure |
| Temperature dysregulation | Autonomic output impaired | PVN → Brainstem pathway |
Hypothalamic dysfunction contributes to AD metabolic features:
Metabolic changes in PD involve hypothalamic dysfunction:
Severe weight loss in HD despite hyperphagia:
Metabolic dysfunction is a prognostic factor in ALS:
| Drug/Compound | Status | Mechanism |
|---|---|---|
| Setmelanotide | FDA approved (rare obesity) | MC4R agonist |
| Tirzepatide | FDA approved (diabetes/obesity) | GLP-1/GIP (indirect POMC activation) |
| Semaglutide | FDA approved (diabetes/obesity) | GLP-1R agonist (indirect POMC) |
| Test | Relevance to POMC |
|---|---|
| Fasting leptin | Reflects adipose mass, resistance state |
| Insulin/glucose | Glucose homeostasis, insulin sensitivity |
| α-MSH levels | Low in PWS, not routinely measured |
| NPY levels | Elevated in PWS |
Hypothalamic MRI: Volume assessment in PWS
Functional MRI: Response to food cues
PET imaging: Hypothalamic metabolism
Neurons — Major brain cell type](/entities/neurons)